COGNIS TONALIN Conjugated Linoleic Acid Does Not Infringe Loders Patents

Dusseldorf, February 18, 2003 - Cognis, a global specialty chemicals and nutritional ingredients company, has become aware of the lawsuit initiated by Loders Croklaan against Natural Inc. for alleged violation of Loders’ patents regarding the manufacture of Conjugated Linoleic Acid (CLA). Cognis wishes to alleviate any confusion our customers may have regarding the COGNIS’ TONALIN® CLA brand due to Loders’ recent press release concerning their lawsuit against Natural.

TONALIN® CLA is currently manufactured by Cognis under the terms of a recently implemented licensing agreement between Cognis and Natural. The processes used by Cognis are proprietary developments which have been designed to ensure the integrity and consistent quality of TONALIN® CLA. At the same time, they clearly do not infringe the Loders Croklaan patents.

For information in North America about TONALIN® brand CLA, please call 800.673.3702 to place an order, e-mail [email protected], or fax 513.482.3576. For information in Europe about TONALIN® brand CLA, call +49.211.794.9692, e-mail [email protected], or fax +49.211.798.2390. For information in Asia Pacific about TONALIN® brand CLA, call +61.3.9584.4588.

About Cognis:

Cognis ( is a worldwide supplier of innovative specialty chemicals and nutritional ingredients with almost 9,100 employees in close to 50 countries. The company has dedicated its activities to a high level of sustainability and delivers natural-source ingredients for food, nutrition and healthcare markets and serves major customers in the cosmetics, detergents and cleaners industries. Additionally, Cognis provides solutions for a number of other industries such as, coatings and inks, lubricants, textiles and plastics as well as agrosolutions and mining chemicals.

Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and Schroder Ventures Life Sciences. In 2001, Cognis recorded sales of 3.1 billion euros and an operating profit of 174 million euros. In the first nine months of 2002, sales were 2.4 billion euros.

Cognis Nutrition and Health, a business unit of Cognis Group, provides antioxidant, botanical and nature-based ingredients for dietary supplements; pharmaceuticals and healthcare; functional foods and medical nutrition; and animal nutrition. As a leader in food technology, Cognis manufactures emulsifiers, emulsifier-based compounds, and numerous other specialty products for the food industry worldwide.

Contacts at Cognis:

Paul Allen, Group Vice President, Cognis Nutrition & Health

Phone: +1-513-482-3004
e-mail: [email protected]

Susanne Sengel, Manager, Cognis Corporate Communications

Phone: +49-211-7940 5431
e-mail: [email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.